Skip to main content
. 2020 Jan 9;12(1):161. doi: 10.3390/cancers12010161

Figure 1.

Figure 1

Drug binding affinity for carbonate apatite (CA) nanoparticles (NPs), citrate-modified CA (CMCA) NPs, and α-ketoglutaric acid-modified CA (α-KAMCA) NPs. (A) Estimation of cyclophosphamide (CYP) binding affinity for CA NPs, CMCA NPs, and α-KAMCA NPs. (B) Estimation of doxorubicin (DOX) binding affinity for CA NPs, CMCA NPs, and α-KAMCA NPs.